Medicus Pharma submits optimized Phase 2 study for Teverelix to FDA

April 6, 2026 7:31 AM

Medicus Pharma Ltd. (NASDAQ: MDCX) submitted an optimized Phase 2 clinical study protocol to the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found